Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.20.

A number of equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm reaffirmed a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Finally, Scotiabank began coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price objective for the company.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the period. Benedict Financial Advisors Inc. bought a new stake in shares of Gain Therapeutics in the fourth quarter worth about $35,000. Sprott Inc. acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth about $30,000. Jones Financial Companies Lllp lifted its holdings in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $198,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Stock Up 4.3 %

Shares of NASDAQ GANX opened at $2.20 on Friday. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.63. The firm’s 50-day moving average is $2.23 and its 200-day moving average is $1.97. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $58.36 million, a PE ratio of -2.00 and a beta of 0.14.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.